ARCHIVES

FDA Rile Changes Reporting Requirements for Adverse Events

This article is from The Cancer Letter archive.

Vol. 20 No. 44 | November 18, 1994

Download PDF Visit The Full Archive

Related Articles

Women’s Health Initiative Trial Produced $37.1 Billion in Returns

May 9, 2014

Text of Peer Review Of Medenica’s Treatment Of Breast Cancer Patient

April 30, 1993

Sentinel Lymph Node Excision Has No Impact on Survival

August 26, 2011

DCT Board Ok’s concept For In Vivo Combination Studies

November 23, 1990

New Awards for New Investigators To Replace R-23 Grants

November 8, 1985

BRCA2 Carriers Reduced BC Risk By Prophylactic Surgery

June 30, 2006